ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01903330

Recruitment Status : Unknown

Verified May 2022 by Epitopoietic Research Corporation.
Recruitment status was: Active, not recruiting

First Posted : July 19, 2013

Last Update Posted : May 16, 2022

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

University of California, Irvine

Information provided by (Responsible Party):

Epitopoietic Research Corporation

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	March 2023
Estimated Study Completion Date :	March 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA, Stathopoulos A. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine. 2015 May 28;33(23):2690-6. doi: 10.1016/j.vaccine.2015.03.095. Epub 2015 Apr 10.

To Top